EGFR and breast cancer: To distinguish between hard-wired isoform ratios and inducible promoter switching, we applied EGF or GW2974, a dual EGFR/ErbB-2 kinase inhibitor, on MCF10A cells, on another non-tumorigenic mammary cell line, and on nine breast cancer lines.